A rapid and sensitive method for determination of methylene-diphosphonate in rat bone using liquid chromatography-mass spectrometry.

Derivatization LC-MS/MS Methylene-diphosphonate Pharmacokinetics Tetramethyl Phosphonate

Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
30 Nov 2023
Historique:
received: 16 06 2023
revised: 12 09 2023
accepted: 14 09 2023
pubmed: 22 9 2023
medline: 22 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the determination of methylene-diphosphonate (MDP) in rat bone. This method employed derivatization of MDP and allowed rapid and sensitive quantification of MDP in rat shin bone. The analyte was extracted from the bone tissues with phosphoric acid and derivatized to MDP tetramethyl phosphonate using trimethylsilyl diazomethane (TMS-DAM). MDP tetramethyl phosphonate was then quantified by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), with high selectivity, accuracy, and precision. The total run time was 6.5 min. The lower limit of quantification was 2.00 ng/mL. The intra- and inter-assay precision (in RSD) calculated from quality control samples was less than 15%, and the accuracy was between 98.1% and 100.2%. The analytical process for the determination of MDP in rat bone is fully described, which is a pivotal step for further biomedical research on MDP.

Identifiants

pubmed: 37734256
pii: S0731-7085(23)00496-X
doi: 10.1016/j.jpba.2023.115727
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115727

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Linqi Zhang (L)

XPiscoric Inc., 319 Qingpi Avenue, Wenjiang District, Chengdu, Sichuan 611130, PR China.

Yonglong Zeng (Y)

Chengdu Yunke Pharmaceutical CO.,LTD, 505 West Fucheng Avenue, Bldg 1 Rm 1-2302, Chengdu, Sichuan 610041, PR China.

Yan Zeng (Y)

Chengdu Yunke Pharmaceutical CO.,LTD, 505 West Fucheng Avenue, Bldg 1 Rm 1-2302, Chengdu, Sichuan 610041, PR China.

Dan Hu (D)

XPiscoric Inc., 319 Qingpi Avenue, Wenjiang District, Chengdu, Sichuan 611130, PR China.

Hengmao Liu (H)

XPiscoric Inc., 319 Qingpi Avenue, Wenjiang District, Chengdu, Sichuan 611130, PR China.

Rui Peng (R)

XPiscoric Inc., 319 Qingpi Avenue, Wenjiang District, Chengdu, Sichuan 611130, PR China.

Xiaofang Liang (X)

XPiscoric Inc., 319 Qingpi Avenue, Wenjiang District, Chengdu, Sichuan 611130, PR China.

Jianyu Liu (J)

XPiscoric Inc., 319 Qingpi Avenue, Wenjiang District, Chengdu, Sichuan 611130, PR China. Electronic address: liu.jianyu@xpiscoric.com.

Classifications MeSH